News from AMTRA

VMD Medicines Update

The VMD are publishing 6 months’ worth of medicines update information on their VMD connect website 

Information includes a rolling 6-month of summaries of changes of new marketing authorisations and changes to existing authorisations that relate to the safe use of the product is at www.vmdconnect.uk/medicines-update. You can find it under the ‘vet practice & supply’ tab at the top of the page.

Their website enhances the guidance and services already available on gov.uk/vmd and provides a deeper insight into the work of the VMD.

RAMAs/SQPs, vets and other prescribers and para-professionals can access links directly to updated SPCs and easily pass on publicly available information to clients.

Please do check the site for relevant updates: vmdconnect.uk/medicines-update 

There have been some VPS-specific amends and registrations over the summer including 

Vectra 3D Spot-on Solution for Dogs (Range)

Ceva Animal Health Ltd          GB       NFA-VPS

Section 4.5ii: Modification of an existing user safety warning to read as follows: ‘Laboratory studies in rabbits and rats with the excipient N-methyl pyrrolidone have shown evidence of foetotoxic effects. The veterinary medicinal product should not be administered by pregnant women and women suspected of being pregnant.

Personal protective equipment consisting of gloves should be worn when handling the veterinary medicinal product by women of childbearing age.

Section 4.5i: Laboratory studies in rabbits and rats with the excipient N-methyl pyrrolidone have shown evidence of foetotoxic effects. Use only according to the benefit-risk assessment by the responsible veterinarian.

The range consists of: 

  • Vectra 3D Spot-on Solution for Dogs 1.5-4 kg
  • Vectra 3D Spot-on Solution for Dogs 4-10 kg
  • Vectra 3D Spot-on Solution for Dogs 10-25 kg
  • Vectra 3D Spot-on Solution for Dogs 25-40 kg
  • Vectra 3D Spot-on Solution for Dogs >40 kg